PMID- 21332943
OWN - NLM
STAT- MEDLINE
DCOM- 20110606
LR  - 20110404
IS  - 1742-4658 (Electronic)
IS  - 1742-464X (Linking)
VI  - 278
IP  - 8
DP  - 2011 Apr
TI  - Oligomannose-coated liposomes efficiently induce human T-cell leukemia 
      virus-1-specific cytotoxic T lymphocytes without adjuvant.
PG  - 1358-66
LID - 10.1111/j.1742-4658.2011.08055.x [doi]
AB  - Human T-cell leukemia virus-1 (HTLV-1) causes adult T-cell leukemia/lymphoma, 
      which is an aggressive peripheral T-cell neoplasm. Insufficient T-cell response 
      to HTLV-1 is a potential risk factor in adult T-cell leukemia/lymphoma. Efficient 
      induction of antigen-specific cytotoxic T lymphocytes is important for 
      immunological suppression of virus-infected cell proliferation and oncogenesis, 
      but efficient induction of antigen-specific cytotoxic T lymphocytes has evaded 
      strategies utilizing poorly immunogenic free synthetic peptides. Here, we 
      examined the efficient induction of an HTLV-1-specific CD8+ T-cell response by 
      oligomannose-coated liposomes (OMLs) encapsulating the human leukocyte antigen 
      (HLA)-A*0201-restricted HTLV-1 Tax-epitope (OML/Tax). Immunization of HLA-A*0201 
      transgenic mice with OML/Tax induced an HTLV-1-specific gamma-interferon 
      reaction, whereas immunization with epitope peptide alone induced no reaction. 
      Upon exposure of dendritic cells to OML/Tax, the levels of CD86, major 
      histocompatibility complex class I, HLA-A02 and major histocompatibility complex 
      class II expression were increased. In addition, our results showed that 
      HTLV-1-specific CD8+ T cells can be efficiently induced by OML/Tax from HTLV-1 
      carriers compared with epitope peptide alone, and these HTLV-1-specific CD8+ T 
      cells were able to lyse cells presenting the peptide. These results suggest that 
      OML/Tax is capable of inducing antigen-specific cellular immune responses without 
      adjuvants and may be useful as an effective vaccine carrier for prophylaxis in 
      tumors and infectious diseases by substituting the epitope peptide.
CI  - (c) 2011 The Authors Journal compilation (c) 2011 FEBS.
FAU - Kozako, Tomohiro
AU  - Kozako T
AD  - Division of Hematology and Immunology, Center for Chronic Viral Diseases, 
      Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, 
      Japan. kozako@fukuoka-u.ac.jp
FAU - Hirata, Shinya
AU  - Hirata S
FAU - Shimizu, Yoshitaka
AU  - Shimizu Y
FAU - Satoh, Yuichiro
AU  - Satoh Y
FAU - Yoshimitsu, Makoto
AU  - Yoshimitsu M
FAU - White, Yohann
AU  - White Y
FAU - Lemonnier, Francois
AU  - Lemonnier F
FAU - Shimeno, Hiroshi
AU  - Shimeno H
FAU - Soeda, Shinji
AU  - Soeda S
FAU - Arima, Naomichi
AU  - Arima N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110310
PL  - England
TA  - FEBS J
JT  - The FEBS journal
JID - 101229646
RN  - 0 (Liposomes)
RN  - 0 (Oligosaccharides)
RN  - 0 (oligomannoside)
SB  - IM
MH  - Animals
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Dendritic Cells/immunology
MH  - Female
MH  - HTLV-I Infections/immunology
MH  - Human T-lymphotropic virus 1/*immunology
MH  - Humans
MH  - Leukemia-Lymphoma, Adult T-Cell/immunology
MH  - Liposomes/*pharmacology
MH  - Mice
MH  - Oligosaccharides/*pharmacology
MH  - T-Lymphocytes, Cytotoxic/drug effects/*immunology
EDAT- 2011/02/22 06:00
MHDA- 2011/06/07 06:00
CRDT- 2011/02/22 06:00
PHST- 2011/02/22 06:00 [entrez]
PHST- 2011/02/22 06:00 [pubmed]
PHST- 2011/06/07 06:00 [medline]
AID - 10.1111/j.1742-4658.2011.08055.x [doi]
PST - ppublish
SO  - FEBS J. 2011 Apr;278(8):1358-66. doi: 10.1111/j.1742-4658.2011.08055.x. Epub 2011 
      Mar 10.